Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$5.22 – $5.22
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.86B | $9.38B | $10.52B | $12.06B | $12.63B | $12.43B | $11.81B | $11.60B |
| Cost of revenue | $3.36B | $3.39B | $3.67B | $4.25B | $4.46B | $4.77B | $4.08B | $4.17B |
| Gross profit | $5.50B | $5.99B | $6.85B | $7.81B | $8.17B | $7.66B | $7.73B | $7.43B |
| Gross margin | 62.1% | 63.9% | 65.1% | 64.7% | 64.7% | 61.6% | 65.5% | 64.1% |
| R&D | $549.0M | $732.9M | $884.1M | $1.15B | $1.43B | $1.33B | $1.03B | $821.1M |
| Operating income | $1.27B | $1.73B | $2.50B | $2.27B | $2.35B | $2.42B | $2.84B | $2.56B |
| EBITDA | $1.82B | $2.16B | $2.95B | $2.77B | $3.04B | $3.30B | $3.47B | $3.10B |
| Net income | $1.08B | $1.30B | $1.71B | $1.78B | $1.91B | $1.95B | $2.06B | $1.97B |
| Net margin | 12.2% | 13.9% | 16.3% | 14.7% | 15.1% | 15.7% | 17.4% | 17.0% |
| EPS (diluted) | 1.16 | 1.39 | 1.83 | 1.90 | 2.04 | 2.10 | 2.24 | 2.24 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $12.2B | $2.36 | $2.18–$2.46 | 1 |
| 2027 | $12.8B | $2.59 | $2.39–$2.70 | 1 |
| 2028 | $13.5B | $2.88 | $2.67–$3.00 | 1 |
Forward consensus · source: Financial Modeling Prep
LIVZON PHARMACEUTICAL GRP
No one on the platform currently holds LVZPF.
No tracked institution reports a position in LVZPF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-06-17 | $1.6430 | 2026-07-13 |
| 2025-06-16 | $1.1988 | 2025-07-11 |
| 2024-07-09 | $1.4820 | 2024-08-05 |
| 2023-07-03 | $1.7438 | 2023-07-31 |
| Execution date | Ratio |
|---|---|
| 2018-06-25 | 13-for-10 |
No one on the platform has traded LVZPF yet.
| +0.00% |
| $4.4B |
| — |
| HLBBFH. Lundbeck A/S | $6.60 | +0.00% | $5.2B | — |
| HLUBFH. Lundbeck A/S | $5.50 | +0.00% | $5.8B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.